

## PRESS RELEASE

### EMED alleges RMS's HlgH-Flo™ sets infringe EMED's newly issued patent in a lawsuit filed yesterday

*The new lawsuit underscores prior litigation against RMS*

El Dorado Hills, California, November 8th 2017: EMED is pleased to announced yesterday the USPTO issued US 9,808,576; a new patent that complements EMED's needle securement Intellectual Property portfolio. In continuing its business objective of vigorously defending its intellectual property, EMED filed a patent infringement on November 7, 2017 against Repro-Med Systems, Inc. (dba RMS Medical Products) alleging its "HlgH-Flo Subcutaneous Safety Needle Sets™" infringe the claims of the newly issued patent. Information about the lawsuit can be found at the Eastern District of Texas under cause number 2:17-cv000728."

For additional information about our patented devices, contact us at [info@emedtc.com](mailto:info@emedtc.com).

***Global legislation is increasing requirements for devices with needles to have safety mechanisms to protect clinicians, caregivers and patients.***

EMED's needle securement technology was originated in the 1990's and it has evolved to include state-of-the art patented designs applicable to Huber sets, Subcutaneous sets and other devices that require needle protection. The invention disclosed and claimed in the '576 Patent allows for the safe removal of needle infusion sets from patients and their safe disposal. In particular, the invention solves the needle safety problem by sheathing the needle within a protective pair of folding wings during and after removal from a patient's skin. The '576 Patent is a continuation of previous EMED patents that cover an array of safety designs.

EMED pioneered the design of home infusion devices for SCIG and has since been working with clinicians to advance the standard of care in Primary Immunodeficiency by means of subcutaneous infusions at the patient's home.

***"The new patent enhances EMED's needle safety Intellectual Property and is available for licensing around the world", said Paul Lambert, CEO of EMED Technologies Corporation.***

EMED is fully committed to investing in the design and development of novel devices to improve the standard of care in infusion therapy. Our pipeline of infusion device platforms offers versatile options for the delivery of pharmaceuticals under specialized and proprietary delivery protocols.

To learn more about EMED visit our website at [www.emedtc.com](http://www.emedtc.com).

#### Press Contact

Name: Joseph Barbrie  
Telephone: 916-932-0071  
Email: [jbarbrie@emedtc.com](mailto:jbarbrie@emedtc.com)